FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 275 filers reported holding FATE THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 0.99 and the average weighting 0.7%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $476,267 | -16.4% | 100,056 | +0.1% | 0.01% | -25.0% |
Q1 2023 | $570,023 | -64.8% | 100,004 | -37.8% | 0.01% | -63.6% |
Q4 2022 | $1,621,645 | -55.0% | 160,718 | 0.0% | 0.02% | -56.0% |
Q3 2022 | $3,602,000 | -9.6% | 160,718 | 0.0% | 0.05% | -18.0% |
Q2 2022 | $3,983,000 | -36.1% | 160,718 | 0.0% | 0.06% | -39.6% |
Q1 2022 | $6,231,000 | -46.5% | 160,718 | -19.3% | 0.10% | -39.5% |
Q4 2021 | $11,648,000 | +28.5% | 199,076 | +30.2% | 0.17% | +12.8% |
Q3 2021 | $9,066,000 | -20.3% | 152,957 | +16.7% | 0.15% | -30.2% |
Q2 2021 | $11,379,000 | +9.2% | 131,106 | +3.8% | 0.21% | -8.2% |
Q1 2021 | $10,418,000 | – | 126,360 | – | 0.23% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JOHNSON & JOHNSON | 3,379,064 | $131,006,000 | 24.77% |
Redmile Group, LLC | 12,957,222 | $502,351,000 | 15.68% |
Grosvenor Holdings, L.L.C. | 1,037,256 | $40,214,000 | 7.85% |
Casdin Capital, LLC | 3,400,000 | $131,818,000 | 5.91% |
Ally Bridge Group (NY) LLC | 181,500 | $7,037,000 | 5.22% |
DAFNA Capital Management LLC | 500,930 | $19,421,000 | 5.06% |
Deep Track Capital, LP | 2,000,000 | $77,540,000 | 4.97% |
Artal Group S.A. | 2,000,000 | $77,540,000 | 3.25% |
Tri Locum Partners LP | 190,345 | $7,380,000 | 2.88% |
ARK Investment Management | 10,988,182 | $426,012,000 | 1.78% |